delNS/Breast Antigens
Breast Cancer
PreclinicalActive
Key Facts
About BlueSky Immunotherapies
BlueSky Immunotherapies is a Vienna-based biotech leveraging its novel delNS viral vector platform to develop immunotherapies for cancer and infectious diseases. Its technology is designed to induce potent interferon responses, activating multiple immune cell types and creating a hostile environment for tumors and viruses. The company has advanced its lead HPV-targeted programs into Phase 1/2 clinical trials and has demonstrated compelling proof-of-concept in a veterinary oncology setting, validating the platform's broad potential.
View full company profileTherapeutic Areas
Other Breast Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| Antifibrotic Therapy Program | MeCo Diagnostics | Pre-clinical |
| inPROBE for HER2 | SDS Optic | Clinical Investigation |
| ACT‑BC1 | Anthrocell | Preclinical |
| APA-1000 Breast Thermotherapy System | Medifocus | Phase III |
| Early‑Detection Breast Cancer Screening | Karkinos Healthcare | Market |
| Unnamed Breast Cancer Program | Click Therapeutics | Pilot/Phase 2 |
| Lerociclib (Lerocliclib) | Chemogenics BioPharma | Phase 3 |
| AT-017 | Asieris Pharmaceuticals | Not Specified |
| CDK2 inhibitor | Acellera | Pre-clinical |
| NP-G2-044 | Novita Pharmaceuticals | Phase 2a |
| Maveropepimut-S (MVP-S) | BioVaxys | Clinical Evaluation |
| Cannabics® BRST-33 | CNBX Pharmaceuticals | Discovery |